FNY Investment Advisers LLC Invests $126,000 in RxSight, Inc. (NASDAQ:RXST)

FNY Investment Advisers LLC acquired a new stake in RxSight, Inc. (NASDAQ:RXST) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 4,400 shares of the company’s stock, valued at approximately $126,000.

Several other large investors have also recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. grew its stake in shares of RxSight by 39.2% in the first quarter. Ameritas Investment Partners Inc. now owns 1,907 shares of the company’s stock worth $32,000 after acquiring an additional 537 shares in the last quarter. California State Teachers Retirement System raised its position in RxSight by 7.4% in the 1st quarter. California State Teachers Retirement System now owns 8,829 shares of the company’s stock valued at $147,000 after purchasing an additional 609 shares in the last quarter. American International Group Inc. boosted its stake in shares of RxSight by 10.7% in the 2nd quarter. American International Group Inc. now owns 9,638 shares of the company’s stock valued at $136,000 after buying an additional 929 shares during the period. HighTower Advisors LLC grew its position in shares of RxSight by 11.0% during the fourth quarter. HighTower Advisors LLC now owns 11,117 shares of the company’s stock worth $141,000 after buying an additional 1,102 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of RxSight by 2.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 53,312 shares of the company’s stock worth $675,000 after buying an additional 1,214 shares during the period. 66.51% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at RxSight

In other news, Director Shweta Maniar sold 4,292 shares of the company’s stock in a transaction that occurred on Tuesday, August 29th. The stock was sold at an average price of $28.06, for a total transaction of $120,433.52. Following the completion of the sale, the director now owns 24,947 shares in the company, valued at $700,012.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Bakker Juliet Tammenoms sold 2,950 shares of the company’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $30.01, for a total transaction of $88,529.50. Following the transaction, the director now owns 20,223 shares of the company’s stock, valued at $606,892.23. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Shweta Maniar sold 4,292 shares of the company’s stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $28.06, for a total transaction of $120,433.52. Following the transaction, the director now directly owns 24,947 shares in the company, valued at $700,012.82. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 61,901 shares of company stock worth $1,839,683. 21.13% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have commented on RXST shares. Bank of America boosted their price target on shares of RxSight from $24.00 to $32.00 in a report on Friday, July 7th. Wells Fargo & Company upped their price target on RxSight from $17.00 to $27.00 in a report on Monday, June 5th. Needham & Company LLC restated a “buy” rating and set a $34.00 price objective on shares of RxSight in a research report on Tuesday, August 8th. Oppenheimer upped their target price on shares of RxSight from $29.00 to $34.00 and gave the company an “outperform” rating in a report on Tuesday, August 8th. Finally, BTIG Research lifted their price target on shares of RxSight from $29.00 to $36.00 in a research note on Monday, July 17th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.50.

RxSight Stock Performance

RxSight stock traded up $0.15 during midday trading on Friday, hitting $29.83. 1,088,222 shares of the company’s stock were exchanged, compared to its average volume of 429,530. The company has a debt-to-equity ratio of 0.12, a quick ratio of 9.81 and a current ratio of 10.89. The stock has a market cap of $1.06 billion, a price-to-earnings ratio of -14.99 and a beta of 0.71. RxSight, Inc. has a 12-month low of $9.78 and a 12-month high of $33.77. The firm’s 50 day simple moving average is $30.29 and its 200 day simple moving average is $24.19.

RxSight (NASDAQ:RXST) last released its quarterly earnings results on Monday, August 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.07. The firm had revenue of $20.81 million for the quarter, compared to analyst estimates of $19.21 million. RxSight had a negative return on equity of 48.72% and a negative net margin of 88.72%. Equities research analysts predict that RxSight, Inc. will post -1.66 EPS for the current year.

About RxSight

RxSight, Inc, an ophthalmic medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.